These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 12409327)

  • 1. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
    Baselga J; Rischin D; Ranson M; Calvert H; Raymond E; Kieback DG; Kaye SB; Gianni L; Harris A; Bjork T; Averbuch SD; Feyereislova A; Swaisland H; Rojo F; Albanell J
    J Clin Oncol; 2002 Nov; 20(21):4292-302. PubMed ID: 12409327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
    Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
    J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I studies of ZD1839 in patients with common solid tumors.
    Lorusso PM
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):21-9. PubMed ID: 12644981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
    Ranson M; Hammond LA; Ferry D; Kris M; Tullo A; Murray PI; Miller V; Averbuch S; Ochs J; Morris C; Feyereislova A; Swaisland H; Rowinsky EK
    J Clin Oncol; 2002 May; 20(9):2240-50. PubMed ID: 11980995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
    Von Pawel J
    Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
    LoRusso PM; Herbst RS; Rischin D; Ranson M; Calvert H; Raymond E; Kieback D; Kaye S; Gianni L; Harris A; Bjork T; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Feyereislova A; Heyes A; Averbuch SD; Ochs J; Baselga J
    Clin Cancer Res; 2003 Jun; 9(6):2040-8. PubMed ID: 12796366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Cohen EE; Rosen F; Stadler WM; Recant W; Stenson K; Huo D; Vokes EE
    J Clin Oncol; 2003 May; 21(10):1980-7. PubMed ID: 12743152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.
    Albanell J; Rojo F; Averbuch S; Feyereislova A; Mascaro JM; Herbst R; LoRusso P; Rischin D; Sauleda S; Gee J; Nicholson RI; Baselga J
    J Clin Oncol; 2002 Jan; 20(1):110-24. PubMed ID: 11773160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program.
    Pallis AG; Mavroudis D; Androulakis N; Souglakos J; Kouroussis C; Bozionelou V; Vlachonikolis IG; Georgoulias V
    Lung Cancer; 2003 Jun; 40(3):301-7. PubMed ID: 12781429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
    Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J
    Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.
    Nakagawa K; Tamura T; Negoro S; Kudoh S; Yamamoto N; Yamamoto N; Takeda K; Swaisland H; Nakatani I; Hirose M; Dong RP; Fukuoka M
    Ann Oncol; 2003 Jun; 14(6):922-30. PubMed ID: 12796031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
    Ahn MJ; Kim DW; Cho BC; Kim SW; Lee JS; Ahn JS; Kim TM; Lin CC; Kim HR; John T; Kao S; Goldman JW; Su WC; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; Yang JC
    Lancet Respir Med; 2017 Nov; 5(11):891-902. PubMed ID: 29056570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
    Herbst RS
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
    Soria JC; Baselga J; Hanna N; Laurie SA; Bahleda R; Felip E; Calvo E; Armand JP; Shepherd FA; Harbison CT; Berman D; Park JS; Zhang S; Vakkalagadda B; Kurland JF; Pathak AK; Herbst RS
    Eur J Cancer; 2013 May; 49(8):1815-24. PubMed ID: 23490650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
    Hotta K; Kiura K; Ueoka H; Tabata M; Fujiwara K; Kozuki T; Okada T; Hisamoto A; Tanimoto M
    Lung Cancer; 2004 Nov; 46(2):255-61. PubMed ID: 15474674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
    Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
    BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
    Reckamp K; Gitlitz B; Chen LC; Patel R; Milne G; Syto M; Jezior D; Zaknoen S
    Cancer; 2011 Feb; 117(4):809-18. PubMed ID: 20922800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
    Shapiro GI; Rodon J; Bedell C; Kwak EL; Baselga J; Braña I; Pandya SS; Scheffold C; Laird AD; Nguyen LT; Xu Y; Egile C; Edelman G
    Clin Cancer Res; 2014 Jan; 20(1):233-45. PubMed ID: 24166903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G; Hirte H; Miller WH; Lorimer IA; Stewart D; Batist G; Parolin DA; Hanna P; Stafford S; Friedmann J; Walsh W; Mathews S; Douglas L; Seymour LK
    Invest New Drugs; 2005 Mar; 23(2):147-55. PubMed ID: 15744591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer.
    Mackenzie MJ; Hirte HW; Glenwood G; Jean M; Goel R; Major PP; Miller WH; Panasci L; Lorimer IA; Batist G; Matthews S; Douglas L; Seymour L
    Invest New Drugs; 2005 Mar; 23(2):165-70. PubMed ID: 15744593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.